A retrospective study of survival of patients (pts) with locally advanced (LA)/metastatic melanoma (MM) treated with immune checkpoint inhibitors
Latest Information Update: 17 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress